Accordingly, our study aimed to evaluate the utility of circulating apelin as a biomarker for sarcopenia by measuring serum apelin levels and conducting comprehensive assessments of muscle phenotypes—muscle mass, strength, and physical performance—which are essential for diagnosing sarcopenia in a cohort of older adults. Here, APLN is linked to sarcopenia.